Technical Analysis for ONC - Oncimmune Holdings Plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Uptrend | Bullish | 0.00% | |
Jack-in-the-Box Bullish | Bullish Swing Setup | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Stochastic Sell Signal | Bearish | -5.15% | |
Expansion Breakout | Bullish Swing Setup | -5.15% | |
Wide Range Bar | Range Expansion | -5.15% |
Alert | Time |
---|---|
Possible Inside Day | about 19 hours ago |
Fell Below Upper Bollinger Band | about 23 hours ago |
Down 5% | about 23 hours ago |
Down 3% | about 23 hours ago |
Down 2% | about 23 hours ago |
Get a Trading Assistant
Oncimmune Holdings Plc Description
Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types. EarlyCDT-Lung is a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. EarlyCDT-Lung test is being used in the randomized trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland Early Childhood Longitudinal Study (ECLS) of over 12,000 high-risk smokers. It is also developing the EarlyCDT tests for other cancers, which include in particular the liver and ovarian cancers. It has sold over 145,000 tests in the United States and the United Kingdom.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Health Medicine Cancer Clinical Medicine Earl Oncology Blood Antibody Biomarker Biomarkers Tumor Cancers Lung Cancer Platform Technology The National National Health Service Nhs Ovarian Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 44.0 |
52 Week Low | 13.0 |
Average Volume | 86,758 |
200-Day Moving Average | 21.42 |
50-Day Moving Average | 21.61 |
20-Day Moving Average | 21.96 |
10-Day Moving Average | 24.02 |
Average True Range | 1.90 |
RSI (14) | 71.99 |
ADX | 25.16 |
+DI | 36.55 |
-DI | 8.75 |
Chandelier Exit (Long, 3 ATRs) | 24.71 |
Chandelier Exit (Short, 3 ATRs) | 21.89 |
Upper Bollinger Bands | 28.02 |
Lower Bollinger Band | 15.90 |
Percent B (%b) | 0.97 |
BandWidth | 55.16 |
MACD Line | 1.68 |
MACD Signal Line | 0.75 |
MACD Histogram | 0.9315 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 29.88 | ||||
Resistance 3 (R3) | 30.09 | 29.55 | 29.50 | ||
Resistance 2 (R2) | 29.55 | 28.97 | 29.44 | 29.37 | |
Resistance 1 (R1) | 28.57 | 28.61 | 28.30 | 28.36 | 29.25 |
Pivot Point | 28.03 | 28.03 | 27.89 | 27.92 | 28.03 |
Support 1 (S1) | 27.05 | 27.45 | 26.78 | 26.84 | 25.95 |
Support 2 (S2) | 26.51 | 27.09 | 26.40 | 25.83 | |
Support 3 (S3) | 25.54 | 26.51 | 25.70 | ||
Support 4 (S4) | 25.32 |